| Not Yet Recruiting | A Phase I/II Study to Evaluate XNW34017 in Patients With Advanced or Metastatic Solid Tumor Advanced Solid Tumors | Phase 1 / Phase 2 | 2026-01-31 |
| Recruiting | A Study of PARG Inhibitor XNW29016 in Patients With Advanced Solid Tumors Who Failed Standard Treatment Tumor, Solid | Phase 1 / Phase 2 | 2025-04-11 |
| Recruiting | A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refrac Relapsed/Refractory Peripheral T Cell Lymphoma | Phase 3 | 2025-04-10 |
| Not Yet Recruiting | To Evaluate XNW5004 Tablets in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma Relapsed/Refractory Peripheral T Cell Lymphoma | Phase 2 | 2024-11-01 |
| Recruiting | Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments Advanced Solid Tumors, Pancreatic Carcinoma, Ovarian Cancer | Phase 1 / Phase 2 | 2023-12-01 |
| Recruiting | Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors W Carcinoma, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma | Phase 1 / Phase 2 | 2023-09-20 |
| Recruiting | XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies. Pancreatic Adenocarcinoma Metastatic, Lung Cancer (NSCLC), Ovarian Cancer | Phase 1 / Phase 2 | 2023-07-27 |
| Recruiting | Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Pros Metastatic Castrate-Resistant Prostate Cancer, mCRPC (Metastatic Castration-resistant Prostate Cancer) | Phase 1 / Phase 2 | 2023-04-19 |
| Unknown | Evaluation of the Efficacy and Safety of Intravenous Imipenem/Cilastatin/XNW4107 in Comparison With Meropenem Complicated Urinary Tract Infection Including Acute Pyelonephritis | Phase 3 | 2023-03-30 |
| Completed | Imipenem/Cilastatin-XNW4107 Versus Imipenem/Cilastatin/Relebactam for Treatment of Participants With Bacterial Hospital Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia | Phase 3 | 2022-07-31 |
| Completed | To Evaluate a Phase I/II Clinical Study of XNW5004 Tablets in Patients With Relapsed/Refractory Advanced Tumor Advanced Tumor, Lymphoma | Phase 1 / Phase 2 | 2021-08-03 |
| Completed | Intrapulmonary Pharmacokinetics of XNW4107, Imipenem and Cilastatin in Healthy Subjects Bacterial Infections | Phase 1 | 2021-03-25 |
| Completed | To Evaluate the Pharmacokinetics of XNW4107 in Healthy Adult Young Females and in Healthy Adult Elderly Males Bacterial Infections | Phase 1 | 2021-03-02 |
| Completed | Pharmacokinetics of XNW4107 in Subjects With Various Degrees of Renal Function Bacterial Infections | Phase 1 | 2021-02-25 |
| Completed | Study to Evaluate Safety, Tolerability, and Pharmacokinetics of XNW4107 Alone or in Combination With Imipenem/ Bacterial Infections | Phase 1 | 2020-07-10 |
| Completed | The the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of XNW3009 in Health Subject Gout | Phase 1 | 2019-11-13 |
| Completed | Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of XNW7201 in Subjects With Adv Advanced Solid Tumors | Phase 1 | 2019-07-01 |